We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer
News

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer
News

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The open-label, multicenter trial is being conducted in the United States and will evaluate Peregrine's bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with broad therapeutic potential, in combination with the chemotherapeutic agent gemcitabine versus gemcitabine monotherapy.

"There is a critical need for new therapeutic options for patients diagnosed with metastatic pancreatic cancer, as median overall survival is limited to 6 months with single-agent chemotherapy," said Shuchi (Susan) Pandya, M.D., a principal investigator of this trial and clinical faculty of Hematology and Oncology at the Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School in Boston. "Prior published data show combining the PS-targeting antibody bavituximab with gemcitabine, a chemotherapy that has been shown to increase PS exposure on tumor blood vessels, enhances anti-tumor effects and controls metastatic growth without added toxicity over gemcitabine alone in animal models of pancreatic cancer. As investigational therapies have yet to prolong survival without causing significant toxicities, we are eager to evaluate this investigational combination therapy in a randomized clinical trial setting."

Currently, Peregrine's bavituximab is being evaluated in combination with chemotherapy in two Phase IIb trials in non-small cell lung cancer, a Phase I/II trial in combination with sorafenib in advanced hepatocellular carcinoma (HCC), as well as a Phase Ib trial for hepatitis C virus (HCV).
"We were inspired to conduct this study based on the encouraging and consistent signs of bavituximab's anti-tumor activity across multiple oncology indications as well as the promising preclinical data supporting the potential of bavituximab in combination with gemcitabine in advanced pancreatic cancer models," said Steven W. King, president and chief executive officer of Peregrine. "With the initiation of our third randomized Phase II oncology trial for bavituximab, we are setting the stage for multiple clinical data reports over the coming year."

Advertisement